JESSICA HAGAN: Open Payments
NPI 1265039366 · RAYVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$498 in 9 payments from 8 companies in 2025. Trend: 2023 $453 · 2024 $198 · 2025 $498
Food & beverage: $498
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 1 | $120 |
| Novo Nordisk Inc | 1 | $103 |
| ABBVIE INC. | 1 | $96 |
| Boston Scientific Corporation | 1 | $92 |
| Amgen Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
| Merck Sharp & Dohme LLC | 1 | $15 |
Products named: Veozah, Ozempic, VRAYLAR, Intracept, OTEZLA, CAPLYTA, Kerendia, M-M-R II.
Industry payments across LA — which companies pay providers there.
